| 2.09 0.19 (10%) | 05-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.45  |
1-year : | 2.86 |
| Resists | First : | 2.09 |
Second : | 2.45 |
| Pivot price | 1.79 |
|||
| Supports | First : | 1.71 |
Second : | 1.47 |
| MAs | MA(5) : | 1.87 |
MA(20) : | 1.76 |
| MA(100) : | 1.79  |
MA(250) : | 2.18 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 70.3 |
D(3) : | 58.8 |
| RSI | RSI(14): 74.5 |
|||
| 52-week | High : | 3.5 | Low : | 1.35 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MDXH ] has closed above the upper band by 26.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 11.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.1 - 2.11 | 2.11 - 2.12 |
| Low: | 1.9 - 1.9 | 1.9 - 1.91 |
| Close: | 2.08 - 2.09 | 2.09 - 2.11 |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Fri, 16 May 2025
MDxHealth SA (NASDAQ:MDXH) Q1 2025 Earnings Call Transcript - Insider Monkey
Thu, 15 May 2025
MDxHealth Earnings Call: Growth Amid Financial Challenges - TipRanks
Thu, 15 May 2025
MDxHealth SA (MDXH) Reports Q1 Loss, Tops Revenue Estimates - MSN
Thu, 15 May 2025
MDxHealth SA (MDXH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Operational ... - Yahoo Finance
Wed, 14 May 2025
MDxHealth Reports Strong Q1 2025 Revenue Growth - TipRanks
Wed, 14 May 2025
MDxHealth SA reports results for the quarter ended March 31 - Earnings Summary - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 3.536e+007 (%) |
| Held by Institutions | 13.2 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.3 |
| Profit Margin | -42.3 % |
| Operating Margin | -18.7 % |
| Return on Assets (ttm) | -10.8 % |
| Return on Equity (ttm) | -345.4 % |
| Qtrly Rev. Growth | 27.5 % |
| Gross Profit (p.s.) | 61115.9 |
| Sales Per Share | 99809.4 |
| EBITDA (p.s.) | -21014.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | 7 (M) |
| PE Ratio | -1.81 |
| PEG Ratio | 0 |
| Price to Book value | 6.96 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 74490 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|